Tomoya Sudo
YOU?
Author Swipe
View article: The Preoperative C-reactive Protein/Albumin Ratio of Immune-inflammation Index Is an Independent Prognostic Factor of Advanced Colorectal Cancer in Older Patients (≥ 65 years)
The Preoperative C-reactive Protein/Albumin Ratio of Immune-inflammation Index Is an Independent Prognostic Factor of Advanced Colorectal Cancer in Older Patients (≥ 65 years) Open
CAR is a useful immune-inflammation index for predicting the prognosis after radical resection for advanced CRC in older patients.
View article: Comprehensive genetic profiling using tissue and blood in locally advanced tumors
Comprehensive genetic profiling using tissue and blood in locally advanced tumors Open
Comprehensive genomic profiling (CGP) aims to assist clinicians with the diagnosis, treatment decisions and early detection of recurrence in patients with cancer. CGP using tumor tissue is widely implemented, whereas circulating tumor DNA …
View article: Comparison of Comprehensive Genomic Profiling Testing “Ion Torrent Genexus Sequencer” With FoundationOne
Comparison of Comprehensive Genomic Profiling Testing “Ion Torrent Genexus Sequencer” With FoundationOne Open
The two cancer genome panels were equivalent but not perfect in terms of the detection of variants using tissue and blood, indicating that different assays and analytical methods may have influenced the results. When performing CGPs, it is…
View article: C-reactive protein/albumin ratio of immune-inflammation index is associated with prognosis of colorectal cancer in older patients (≥ 65 years)
C-reactive protein/albumin ratio of immune-inflammation index is associated with prognosis of colorectal cancer in older patients (≥ 65 years) Open
Purpose We investigated the characteristics of colorectal cancer (CRC) in older patients (≥ 65 years) and the immune-inflammation indexes that are useful for predicting postoperative prognosis. Methods This study included 153 patients aged…
View article: Laparoscopic transabdominal approach for resection of presacral epidermoid cyst in an obese man: a case report
Laparoscopic transabdominal approach for resection of presacral epidermoid cyst in an obese man: a case report Open
Background Complete resection of presacral epidermoid cysts is recommended due to the potential for infection or malignancy. Transsacral and transabdominal approaches have been used to treat presacral tumors. However, there are no standard…
View article: Risk of metachronous colorectal cancer after surgical resection of index rectal cancer in Lynch syndrome: a multicenter retrospective study in Japan
Risk of metachronous colorectal cancer after surgical resection of index rectal cancer in Lynch syndrome: a multicenter retrospective study in Japan Open
Purpose This study evaluated the risk of metachronous colorectal cancer (CRC) after resection of index (first) rectal cancer in patients with Lynch syndrome (LS). Methods Clinicopathological data of patients with genetically proven LS were…
View article: Comparison of Comprehensive Genomic Profiling Testing “Ion Torrent Genexus Sequencer” with FoundationOne
Comparison of Comprehensive Genomic Profiling Testing “Ion Torrent Genexus Sequencer” with FoundationOne Open
Background Molecular diagnostic tests are becoming increasingly routine, and the use of tissue- and blood-based next-generation sequencing (NGS) is integral to the delivery of personalized medicine for targeted cancer therapy. This study a…
View article: Comparison of Anorectal Function and Quality of Life Measures in Patients Following Intersphincteric Resection and Lower Anterior Resection
Comparison of Anorectal Function and Quality of Life Measures in Patients Following Intersphincteric Resection and Lower Anterior Resection Open
This study explored postoperative outcomes for patients with lower rectal cancer who underwent low anterior resection (LAR) or intersphincteric resection (ISR). A total of 49 patients (33 LAR, 16 ISR) were followed using anorectal manometr…
View article: Significance of Desmoplastic Histopathological Growth Pattern for Colorectal Liver Metastases Treated With Preoperative Chemotherapy
Significance of Desmoplastic Histopathological Growth Pattern for Colorectal Liver Metastases Treated With Preoperative Chemotherapy Open
dHGP is useful as a new evaluation method for evaluating the efficacy of preoperative chemotherapy.
View article: Simplified and Optimized Immune Score for Colorectal Cancer Microenvironment
Simplified and Optimized Immune Score for Colorectal Cancer Microenvironment Open
In CRC, TIME evaluation could be simplified by assessing CD3- and CD8-positive T cells in the perimeter of the tumor, and additional FOXP3 evaluation would empower the ability of s-IS evaluation in prognostic assessment.
View article: Supplementary Figure S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Comparison of body weights of 4 experimental groups on day 20 after inoculation. Body weights graph corresponds to Fig. 5A-D.
View article: Supplementary Table S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
IC50 values of fulvestrant, everolimus, AZD8055 and U0126 in ER(+)/HER2(-) and ER(-)/HER2(+) human breast cancer cell lines.
View article: Data from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Data from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Nuclear expression of Y-box–binding protein (YBX1) is closely correlated with clinical poor outcomes and drug resistance in breast cancer. Nuclear translocation of YBX1 is facilitated by YBX1 phosphorylation at serine 102 by AKT, p70S6K, a…
View article: Supplementary Figure S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Comparison of body weights of 4 experimental groups on day 20 after inoculation. Body weights graph corresponds to Fig. 5A-D.
View article: Supplementary Table S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
YBX1 and pYBX1 (S102) expression of 397 invasive breast cancer patients obtained from TCGA (Breast Invasive Carcinoma (TCGA, Provisional).
View article: Supplementary Figure S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Expression of YBX1, pYBX1 and downstream molecules in 6 human breast cancer cell lines.
View article: Supplementary Table S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Overview of pathological diagnosis and treatment status of patients refractory to endocrine therapeutics.
View article: Supplementary Figure S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Expression of YBX1, pYBX1 and downstream molecules in 6 human breast cancer cell lines.
View article: Supplementary Figure S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
The effect of everolimus on expression and phosphorylation of YBX1, ERK/p90RSK and AKT/mTOR signaling molecules in six TNBC cell lines.
View article: Data from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Data from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Nuclear expression of Y-box–binding protein (YBX1) is closely correlated with clinical poor outcomes and drug resistance in breast cancer. Nuclear translocation of YBX1 is facilitated by YBX1 phosphorylation at serine 102 by AKT, p70S6K, a…
View article: Supplementary information from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary information from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Supplementary Materials and Methods
View article: Supplementary Table S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
IC50 values of fulvestrant, everolimus, AZD8055 and U0126 in ER(+)/HER2(-) and ER(-)/HER2(+) human breast cancer cell lines.
View article: Supplementary Figure S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
The effect of everolimus on expression and phosphorylation of YBX1, ERK/p90RSK and AKT/mTOR signaling molecules in six TNBC cell lines.
View article: Supplementary Table S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
YBX1 and pYBX1 (S102) expression of 397 invasive breast cancer patients obtained from TCGA (Breast Invasive Carcinoma (TCGA, Provisional).
View article: Supplementary information from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary information from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Supplementary Materials and Methods
View article: Supplementary Table S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Overview of pathological diagnosis and treatment status of patients refractory to endocrine therapeutics.
View article: Data from MicroRNA-125a-5p Is an Independent Prognostic Factor in Gastric Cancer and Inhibits the Proliferation of Human Gastric Cancer Cells in Combination with Trastuzumab
Data from MicroRNA-125a-5p Is an Independent Prognostic Factor in Gastric Cancer and Inhibits the Proliferation of Human Gastric Cancer Cells in Combination with Trastuzumab Open
Purpose: MicroRNA 125a-5p (miR-125a-5p) has been reported to be a tumor suppressor in malignancies of the breast, ovary, lung, and central nervous system. However, the clinical significance of miR-125a-5p in human gastrointestinal cancer h…
View article: Supplementary Data from MicroRNA-125a-5p Is an Independent Prognostic Factor in Gastric Cancer and Inhibits the Proliferation of Human Gastric Cancer Cells in Combination with Trastuzumab
Supplementary Data from MicroRNA-125a-5p Is an Independent Prognostic Factor in Gastric Cancer and Inhibits the Proliferation of Human Gastric Cancer Cells in Combination with Trastuzumab Open
Supplementary Figures S1-S3; Supplementary Table S1.
View article: Supplementary Table S2 from Contrasting Expression Patterns of Histone mRNA and microRNA 760 in Patients with Gastric Cancer
Supplementary Table S2 from Contrasting Expression Patterns of Histone mRNA and microRNA 760 in Patients with Gastric Cancer Open
XLS file 15K, HIST1H3D expression and clinicopathological factors